NASDAQ · EXELHealthcareBiotechnology

Exelixis financials

$58.65+0.48%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jul 3
Q1 '26
Apr 3
Q4 '25
Jan 2
Q3 '25
Oct 3
Q2 '25
Jul 4
Q1 '25
Apr 4
Q4 '24
Jan 3
Q3 '24
Sep 27
Q2 '24
Jun 28
Q1 '24
Mar 29
Q4 '23
Dec 29
Q3 '23
Sep 29
Revenue$628.7M$610.8M$598.7M$597.8M$568.3M$555.4M$566.8M$539.5M$637.2M$425.2M$479.7M$471.9M
Gross profit$608.0M$590.9M$572.2M$579.2M$548.8M$536.3M$546.8M$522.2M$619.5M$404.0M$457.9M$453.1M
Gross margin96.7%96.7%95.6%96.9%96.6%96.5%96.5%96.8%97.2%95.0%95.5%96.0%
Operating income$248.4M$251.3M$235.2M$236.5M$213.6M$186.9M$163.2M$136.1M$275.9M$29.5M$81.8M-$17.6M
Net income$212.1M$210.5M$244.5M$193.6M$184.8M$159.6M$139.9M$118.0M$226.1M$37.3M$85.5M$1.0M
Net margin33.7%34.5%40.8%32.4%32.5%28.7%24.7%21.9%35.5%8.8%17.8%0.2%
Diluted EPS$0.82$0.79$0.88$0.69$0.65$0.55$0.48$0.40$0.77$0.12$0.27$0.00
EBITDA$255.4M$258.3M$242.9M$263.8M$220.9M$194.2M$171.1M$195.3M$283.7M$68.7M$81.8M-$11.3M
Operating cash flow$307.7M$251.8M$333.5M$290.3M$49.0M$211.4M$240.3M$271.3M$119.5M$68.8M$133.1M-$5.1M
Free cash flow$300.9M$250.3M$332.4M$288.8M$46.2M$208.5M$236.3M$263.1M$117.6M$50.6M-$2.6M-$14.5M
Diluted shares259.7M267.3M276.3M278.5M284.4M288.2M293.5M291.5M294.0M305.5M313.0M319.2M

Balance sheet

Period endJul 3Apr 3Jan 2Oct 3Jul 4Apr 4
Cash & equivalents$281.4M$226.2M$482.5M$376.3M$164.4M$183.8M
Short-term investments$557.9M$551.1M$576.6M$612.2M$626.7M$847.6M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$2.49B$2.59B$2.84B$2.82B$2.68B$2.84B
Total liabilities$650.5M$657.8M$683.1M$662.8M$644.5M$706.2M
Shareholders' equity$1.84B$1.94B$2.16B$2.16B$2.03B$2.13B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology